A novel bispecific T-cell engager(BiTE)has been developed as an efficient immunotherapeutic molecule specifically bringing the T-cell and the tumor target together for enhanced immunotherapy.The general BiTE construct consists of two single-chain variable antibody fragments(scFvs)targeting a tumor-...
The CD3/CD19 BiTE® is a biopharmaceutical drug known as a Bi-specific T-cell engager for a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It binds to CD19 on cancer cells (e.g. Raji cells) and CD3 on T cells simultaneously,...
T celltumor-specific antigenImmuno﹐ncology therapies engage the immune system to treat cancer. BiTE (bispecific Tヽell engager) technology is a targeted immuno﹐ncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation ...
In 2014, Yu et al. published the first study of a T cell engager-armed oncolytic virus. This study introduced an oncolytic Vaccinia virus (VV) encoding an EphA2-targeted T cell engager (EphA2-TEA-VV) [70]. The BiTE sequence featured scFvs targeting the human CD3-ε chain and an EphA...
Here we treated six patients with multidrug-resistant rheumatoid arthritis (RA) with the CD19xCD3 BiTE blinatumomab under compassionate use. Low doses of blinatumomab led to B cell depletion and concomitant decrease of T cells, documenting their engager function. Treatment was safe, with brief...
双特异性T细胞连接抗体(BiTE,Bispecific T-cell Engager):一种特定类型的双抗,一端结合肿瘤细胞,另一端结合T细胞,促进免疫细胞直接攻击肿瘤细胞。 2. 作用机制: 双抗可以通过将免疫细胞(如T细胞或自然杀伤细胞)与肿瘤细胞或其他靶细胞直接连接起来,从而增强免疫细胞对肿瘤的杀伤能力。
The schematic representation of structure and mechanism of action of canonical bispecific T-cell engager (BiTE). mAb: Monoclonal antibody; VH: Heavy chain variable region; VL: Light chain variable region; TAA: Tumor-associated antigen Full size image ...
The bispecific T-cell engager (BITE) construct αB7-H3-αCD3, targeting B7-H3 and CD3, was designed to incorporate a signal peptide followed by the codon-optimized cDNA sequences encoding αB7-H3, derived from a humanized version of the hu8H9 single-chain variable fragment (scFv) [31], ...
ORIGINAL RESEARCH ARTICLEBlinatumomab, a Bispecif i c T-cell Engager (BiTE ? ) for CD-19Targeted Cancer Immunotherapy: Clinical Pharmacology and ItsImplicationsMin Zhu 1 • Benjamin Wu 1 • Christian Brandl 2 • Jessica Johnson 1 •Andreas Wolf 2 • Andrew Chow 1 • Sameer Doshi 1...
Recent clinical data demonstrate the significance of T cells in anti-tumor activity. For instance, the CD19/CD3 bispecific T cell engager (BiTE) blinatumomab is a proven means of harnessing T cells for cancer treatment. BiTE antibody con... SL Ross,M Mulen,PL Mcelroy,... - 《Cancer Resea...